Clinical Trials Browser

Phase 1 × INDUSTRY × vosaroxin × Clear all

NCT00246662 2017-03-30

Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00091585 2007-05-10

Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

Phase 1 Completed

Tumor-Agnostic

Neoplasms

NCT00094159 2007-05-10

Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors

Phase 1 Completed

Tumor-Agnostic

Neoplasms